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ABSTRACT 
Helicobacter pylori is a strong and well-established risk factor for gastric cancer, but seems 
to decrease the risk of oesophageal adenocarcinoma. Thus, eradication treatment for 
Helicobacter pylori may decrease the risk of gastric cancer, and increase the risk of 
oesophageal adenocarcinoma. The aim of this thesis was to examine how eradication 
treatment influences the risk of these tumours in various settings and different study designs.  
Study I assessed the risk of gastric cancer after Helicobacter pylori eradication treatment in a 
systematic review and meta-analysis. Relevant literature was collected from PubMed, Web of 
Science, Embase and the Cochrane Library. The results of eight eligible cohort studies in 
predominantly Asian populations showed a risk decrease of more than 50% after eradication 
treatment for Helicobacter pylori (risk ratio (RR) 0.46, 95% confidence interval (CI) 0.32-
0.66).  
Study II described prescription patterns of Helicobacter pylori eradication treatment in the 
Swedish population based on nationwide data from the Prescribed Drug Registry. From 2005 
to 2014 there were 140,391 individuals (1.5% of the Swedish population) receiving 
eradication treatment, with a decreasing use during the study period. Nearly all eradications 
(95.4%) used the standard triple therapy with a proton pump inhibitor and the antibiotics 
clarithromycin and amoxicillin, also for repeated eradication episodes (92.7%).  
Studies III and IV were Swedish nationwide, population-based cohort studies based on the 
Prescribed Drug Registry, Cancer Registry, Causes of Death Registry and the Patient 
Registry. The risks of gastric adenocarcinoma (Study III), as well as oesophageal 
adenocarcinoma, oesophageal squamous cell carcinoma and the premalignant condition 
Barrett’s oesophagus (Study IV) in the cohort of individuals who received Helicobacter 
pylori eradication treatment were compared to the risks in the corresponding Swedish general 
population. Study III showed a nearly 70% decrease in gastric adenocarcinoma risk from five 
years after eradication treatment (Standardised Incidence Ratio (SIR) 0.31, 95% CI 0.11-
0.67), indicating that this treatment is effective also in a Western population. Study IV 
showed a decreased risk of oesophageal adenocarcinoma (SIR 0.17, 95% CI 0.00-0.92) and 
Barrett’s oesophagus (SIR 0.71, 95% CI 0.45-1.05) five years after eradication treatment, 
which was in contrast to the hypothesis. A decreasing trend was suggested also for 
oesophageal squamous cell carcinoma.  
In conclusion, this thesis has indicated that eradication treatment for Helicobacter pylori 
prevents gastric cancer development both in Asian populations and in the Swedish 
population. There was no evidence that eradication treatment increases the risk of 
oesophageal adenocarcinoma, Barrett’s oesophagus or oesophageal squamous cell carcinoma. 
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1 INTRODUCTION 
Gastric cancer is the fifth most common malignancy and the third most common cause of 
cancer death worldwide. The strongest risk factor for developing gastric cancer is infection 
with the bacterium Helicobacter pylori, with 89% of all non-cardia gastric cancers being 
attributable to this bacterium.(1) However, Helicobacter pylori has been associated with a 
decreased risk of oesophageal adenocarcinoma, a highly lethal cancer with an increasing 
incidence over the past decades. This can probably be explained by a decrease in gastro-
oesophageal reflux as a result of gastric atrophy caused by Helicobacter pylori, decreasing 
gastric acid production. In Sweden (and many other Western countries) the incidence of 
oesophageal adenocarcinoma is currently higher than that of oesophageal squamous cell 
carcinoma. The latter histological type of oesophageal cancer accounts for 87% of 
oesophageal cancer cases worldwide and is not associated with Helicobacter pylori.(2)  
Helicobacter pylori is estimated to be present in the gastric tissue of around half of the human 
population. The prevalence in Sweden is lower at approximately 16% according to recent 
estimates.(3) The largest part of individuals with Helicobacter pylori will not show any 
symptoms from the infection.  
The recommended treatment for Helicobacter pylori is a 7 to 14 day eradication treatment, 
most often consisting of a proton pump inhibitor and two to three antibiotics. Some data 
indicate that eradication treatment may decrease the risk of gastric cancer by 30-50%,(4, 5) 
but this needs to be evaluated in further research. The risk of oesophageal adenocarcinoma 
after Helicobacter pylori eradication treatment has not been studied before.  
The aims of this thesis were to clarify the risk of gastric and oesophageal cancer after 
eradication treatment for Helicobacter pylori.  
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2 BACKGROUND 
2.1 HELICOBACTER PYLORI 
2.1.1 History 
The bacterium Helicobacter pylori was discovered in 1982 by Barry Marshall and Robin 
Warren, when they were the first to link its presence in the gastric tissue of patients with 
gastritis and peptic ulcers to these conditions.(6) They published their findings in The Lancet 
in 1984, and in 2005 they received the Nobel Prize in Physiology or Medicine for their 
discovery. The bacterium was previously noticed by other researchers, but thus far no one 
had made the connection between this infection and peptic ulcer disease. At the time of 
discovery, the bacterium was first named Campylobacter pyloridis. In 1987, the name 
became Campylobacter pylori, until in 1989 it was discovered by genome sequencing that the 
bacterium was not supposed to be a part of the Campylobacter genus and it finally was 
named Helicobacter pylori. Not long after its discovery, it became clear that Helicobacter 
pylori is an important causative agent for gastric cancer and it was classified as a definite 
class I carcinogen by the International Agency for Research on Cancer (IARC) in 1994.(7)      
2.1.2 Epidemiology 
Helicobacter pylori is estimated to be present in the stomach of more than 50% of the human 
population.(8) A systematic review and meta-analysis published in 2017 aimed at mapping 
worldwide Helicobacter pylori prevalence contains data published between 1970 and 
2016.(9) Globally, the highest prevalence is found in Central Asia (79.5%) and Africa 
(79.1%), while the lowest prevalence is found in Oceania (24.4%), Western Europe (34.3%) 
and North America (37.1%).(9) The countries with the highest described prevalence are 
Nigeria (87.7%), Portugal (86.4%) and Estonia (82.5%). Countries with the lowest 
prevalence are Switzerland (18.9%), Denmark (22.1%), and New Zealand (24.0%).(9) 
Helicobacter pylori prevalence in Sweden was 26.2% with a 95% confidence interval (CI) of 
18.3-34.1% as reported from a random effects meta-analysis on 6 different studies with data 
from 1991-2001.(9) Another Swedish study that included data from 2012 reported an overall 
prevalence of Helicobacter pylori of 15.8%.(3) This study also indicated that over the last 
two decades, the prevalence had decreased by more than 20% in Sweden.(3) A similar 
decrease in prevalence was also seen in Europe overall, North America and Oceania, but not 
in Asia and Latin America.(9) In general, Helicobacter pylori prevalence is higher in older 
adults compared to young adults.(10)      
2.1.3 Aetiology 
Helicobacter pylori is usually acquired early in life, before the age of 10, by person-to-person 
transmission.(11) It is believed that transmission occurs orally via saliva, for example by 
using the same kitchen utensils or eating from the same pot, or via faeces or vomit, for 
example from a faeces contaminated water source. Transmission is more likely to occur in 
individuals that grow up in an environment with low socioeconomic status,(12) crowded 
 3 
living conditions and lack of access to running water.(13) Apart from these environmental 
factors, twin research has also shown a role for genetics in acquiring Helicobacter pylori.(14) 
2.1.4 Microbiology 
Helicobacter pylori is a gram-negative, spiral shaped bacterium with flagella (Figure 1). It is 
able to survive in the stomach due to the bacterial enzyme urease that breaks down urea in the 
stomach into ammonia and carbon dioxide. These basic substances neutralise gastric acid and 
form a protection around the bacterium. It can then enter the gastric mucosa and move 
through this layer with the help of its flagella. There the bacterium is able to attach to the 
gastric epithelium.(15) Strains with different levels of virulence have been found, depending 
on the expression of proteins like vacuolating cytotoxin (VacA) and the oncoprotein 
cytotoxin-associated gene A (CagA). These highly virulent strains have been associated with 
an increased risk of gastric cancer and peptic ulcer disease.(16, 17)   
 
 
Figure 1. Helicobacter pylori. Drawing by the author ©. 
 
2.1.5 Diagnosis 
Indications for testing for the presence of Helicobacter pylori are peptic ulcer disease, early 
gastric cancer or mucosa-associated lymphoid tissue (MALT) lymphoma. Some guidelines 
also advise testing in dyspeptic individuals less than 60 years old without alarm symptoms 
like weight loss. Testing with non-invasive methods may be initiated immediately in 
individuals below 50 years of age without alarm symptoms who present with dyspepsia. This 
‘test-and-treat’ strategy is recommended over prescribing a proton pump inhibitor (PPI) or 
endoscopy in this patient group.(18, 19)  
Flagella 
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Both invasive and non-invasive methods can be used to detect the presence of Helicobacter 
pylori. The non-invasive test that has the highest sensitivity and specificity is the urea breath 
test.(20) This test is based on the knowledge that Helicobacter pylori possesses the enzyme 
urease, which allows it to break down urea into ammonia and carbon dioxide. During the test, 
a patient is given urea orally, after which the amount of labelled carbon dioxide is measured 
in the exhaled breath. Another non-invasive test with high sensitivity and specificity when 
using ELISA, is the monoclonal stool antigen test. Here the presence of Helicobacter pylori 
is tested for using a stool sample. For both these tests, the use of a PPI has to be discontinued 
two weeks in advance in order to prevent false-negative results. Serology is an often used 
method to detect Helicobacter pylori because it is readily available and in contrast to most 
other test, the results remain reliable in patients with atrophic gastritis, gastrointestinal 
bleeding, gastric MALT lymphoma and gastric cancer. However, the sensitivity and 
specificity vary locally and therefore serology has to be validated in each setting. Rapid 
serological test are not yet approved for diagnostic use.  
Endoscopy with biopsies is an invasive method to detect Helicobacter pylori. This has the 
advantage that it allows for assessment of the histology of the gastric mucosa at the same 
time. The biopsies can also be used for culture and the rapid urease test. This test can be 
performed during the endoscopy, giving immediate results. It is based on the same concept as 
the urea breath test, where the breakdown of urea by Helicobacter pylori will increase the pH 
of the test medium. Thus, any use of a PPI also has to be discontinued two weeks before the 
endoscopy.  
The success of eradication should be proven in all individuals with a test at least 4 weeks 
after finishing the antibiotic treatment. Recommended tests in this context are the urea breath 
test, the stool antigen test or endoscopy with biopsies.  
2.1.6 Treatment 
Treatment for Helicobacter pylori, called eradication, is initiated after a positive test result. 
Therefore it is important that the indications for testing are followed. Standard eradication 
treatment is triple therapy using a PPI in combination with two antibiotics; clarithromycin, 
and amoxicillin or metronidazole in case of penicillin allergy.(18) However, this treatment 
has become less effective in most parts of the world because of the increasing clarithromycin 
resistance, except for in Northern Europe (including Sweden) where clarithromycin 
resistance is still low.(18, 21) The latest available resistance rates for Helicobacter pylori in 
Sweden are 2% for clarithromycin, 16% for metronidazole and 0% for amoxicillin.(21) 
International guidelines advice against the use of clarithromycin-based triple therapy in areas 
with high clarithromycin resistance, defined as more than 15%.(18, 22) Global resistance 
rates for Helicobacter pylori are 1-25% for clarithromycin, 10-80% for metronidazole and 
less than 1% for amoxicillin.(23) In case of high clarithromycin resistance, the first step is to 
consider the metronidazole resistance in the area. If this is low, triple therapy can be given 
using the antibiotics amoxicillin and metronidazole.(18) In case of high antibiotic resistance 
for both clarithromycin and metronidazole, eradication treatment can be given as quadruple 
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therapy with a PPI, two antibiotics and bismuth, or without bismuth using a PPI and three 
antibiotics.(18, 22) Another recommended second line option is levofloxacin-based 
treatment.(22) Sometimes sequential therapy is given, where the antibiotics are administered 
one after the other, but superior efficacy has not been shown.(18) Recommended antibiotics 
in case of high resistance are tetracycline, levofloxacin, rifabutin, and furazolidone.(18) If 
eradication fails with standard triple therapy, one of the above-mentioned treatments can be 
prescribed. Repeating the same regimen is not meaningful.(24) If the second line treatment 
also fails, resistance testing should be performed to guide further treatment.(18) 
Eradication treatment in Sweden is currently given for a duration of 7 days as recommended 
by local guidelines.(25, 26) However, several meta-analyses have shown that 10 and 14 day 
treatments achieved higher eradication rates than 7 day treatment, with the highest success 
rates found after 14 days of treatment.(18, 27-29) 
2.1.7 Association with gastric and oesophageal cancer and related health 
conditions 
In all individuals infected with Helicobacter pylori, the bacterium will cause chronic gastritis, 
which can later develop into associated conditions like atrophic gastritis, peptic ulcer disease, 
gastric cancer and MALT lymphoma.(18) Since the majority of individuals with 
Helicobacter pylori will not develop any symptoms, the bacterium is sometimes considered 
to be non-pathogenic, and thus not considered an infection.(30)   
Soon after its discovery it became clear that Helicobacter pylori was a causal factor for the 
development of peptic ulcer disease.(31, 32) Helicobacter pylori is associated with 
approximately 95% of duodenal ulcers and 70% of gastric ulcers.(33) Around 10% of all 
individuals with Helicobacter pylori develop peptic ulcer disease.(34)  
Helicobacter pylori infection has been shown to be a risk factor for gastric cancer in a 
number of studies.(35, 36) Meta-analyses yielded an effect size of around 2 for developing 
gastric cancer in individuals with Helicobacter pylori.(37, 38) The mechanism by which the 
bacterium causes cancer is not completely clear. Most likely there are different factors that 
play a role, for example bacterial characteristics like the virulence of the strain,(39) genetic 
factors of the infected individual that determine immune responses, and environmental 
factors like dietary differences.(40-42) A report from IARC found that 89% of all non-cardia 
gastric cancers were attributable to Helicobacter pylori.(1) No association between cardia 
cancers and the bacterium has been shown (Figure 2).(8) Despite this evidence supporting a 
causal role of Helicobacter pylori in the development of gastric cancer, only an estimated 3% 
of all infected individuals develop this cancer.(34) This indicates a contributing role for 
bacterial, genetic and environmental factors presented above. Eradication treatment may 
decrease the risk of developing gastric cancer by 30-50%,(4, 5) but this needs to be evaluated 
in further research.   
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Figure 2. The stomach with the gastric cardia indicated between the dotted lines. Drawing by the 
author ©. 
 
Another gastric malignancy that has been shown to have a causal relation with Helicobacter 
pylori is MALT lymphoma.(43, 44) Multiple studies have shown regression of this 
malignancy after eradication treatment for Helicobacter pylori.(45-47) 
An inverse association has been shown with the risk of oesophageal adenocarcinoma. Meta-
analyses have reported an approximately 40% decreased risk of this cancer type in 
individuals with Helicobacter pylori.(48, 49) The explanation for this decreased risk is 
thought to be a decrease in gastro-oesophageal reflux, due to gastric atrophy caused by 
Helicobacter pylori which leads to a decrease in gastric acid production.(50) Also the risk of 
Barrett’s oesophagus, the precursor lesion of oesophageal adenocarcinoma, has been shown 
to be decreased by 30-60% in individuals with Helicobacter pylori.(51, 52) No association 
has been found between Helicobacter pylori and oesophageal squamous cell carcinoma, a 
cancer that is not associated with gastro-oesophageal reflux.(48, 49)    
2.2 GASTRIC CANCER 
With over 1,000,000 new cases and nearly 800,000 deaths in 2018, gastric cancer is the fifth 
most common malignancy and the third most common cause of cancer death globally.(53) 
The highest incidence rates are found in Eastern Asia, while the incidence is lower in 
Northern America, Northern Europe and Africa.(53) The incidence is about two times higher 
in men, compared to women.(53) The overall 5-year survival is less than 30%.(54) Of all 
gastric cancers, over 95% are histologically classified as adenocarcinoma, which is further 
divided into intestinal or diffuse type carcinoma, both of which are associated with 
Helicobacter pylori infection.(39, 55) The development of the diffuse type is not clear, but 
the intestinal type has been shown to develop according to a specific pathway, the Correa 
pathway; from chronic gastritis, gastric atrophy, intestinal metaplasia, and dysplasia to 
invasive adenocarcinoma (Figure 3).(56)  
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Figure 3. Development of the intestinal type of gastric adenocarcinoma according to the Correa 
pathway. Drawing by the author ©.  
 
Helicobacter pylori is the strongest risk factor for gastric cancer. Among other risk factors it 
has been found that a diet high in fruits and vegetables protects against gastric cancer, while a 
diet high in salt can increase the risk.(57-59) Tobacco smoking has also been found to be a 
moderately strong risk factor for gastric cancer.(60) There is a possible acceleration of the 
cancer risk in individuals who smoke and also have a more virulent strain of Helicobacter 
pylori.(61) Low socioeconomic status is also associated with an increased risk of gastric 
cancer.(62)       
2.3 OESOPHAGEAL CANCER 
Oesophageal cancer was diagnosed in nearly 600,000 individuals and a little over 500,000 
deaths occurred worldwide in 2018, making oesophageal cancer the seventh most common 
cancer and the sixth most common cause of cancer death.(53) Oesophageal cancer has a poor 
prognosis with less than 20% surviving 5 years after the diagnosis,(63) and a 5-year survival 
of 30-40% after treatment with curative intent.(64)  
The two main types of oesophageal cancer, adenocarcinoma and squamous cell carcinoma, 
have different aetiologies. Adenocarcinoma usually arises from Barrett’s oesophagus, a 
condition with metaplasia of the cells in the lower part of the oesophagus.(63) The main risk 
factors are gastro-oesophageal reflux and obesity. Chronic reflux can lead to inflammation 
and erosions of the oesophageal mucosa (oesophagitis) and from there Barrett’s oesophagus 
can develop, which is a precancerous condition. Obesity increases the risk of reflux, but is 
also a risk factor for adenocarcinoma by itself.(65) The incidence of oesophageal 
adenocarcinoma has increased during recent decades, particularly in white men in Western 
populations like Western and Northern Europe, Northern America and Oceania.(2) Men are 
around 3-9 times more likely to develop this cancer type than women.(63)  
 
Normal 
gastric 
mucosa 
Chronic 
gastritis 
Gastric 
atrophy 
Intestinal 
metaplasia 
Dysplasia Adenocarcinoma 
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The main risk factors for oesophageal squamous cell carcinoma are smoking and heavy 
alcohol consumption.(66) Globally this histological type represents 87% of all oesophageal 
cancer cases.(2) Most cases occur in Eastern and South-East Asia, and oesophageal squamous 
cell carcinoma is three times more common in men than in women.(2) The incidence has 
been fairly stable over the last decades, but declined in some Western populations.(66)      
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3 AIMS 
The overall aim of the thesis was to assess the risk of gastric and oesophageal cancer after 
eradication treatment for Helicobacter pylori.  
Specific aims of the included studies were: 
 To evaluate the risk of gastric cancer after Helicobacter pylori eradication treatment 
in a systematic review and meta-analysis.  
 To describe the prescription patterns and the antibiotic regimens used for 
Helicobacter pylori eradication in Sweden.  
 To assess the risk of gastric adenocarcinoma after Helicobacter pylori eradication 
treatment in the Swedish population.  
 To determine the risk of oesophageal adenocarcinoma, oesophageal squamous cell 
carcinoma and Barrett’s oesophagus after Helicobacter pylori eradication treatment. 
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4 MATERIALS AND METHODS 
Table 1. Overview of materials and methods used in the studies. 
 Study I Study II Study III Study IV 
Design Systematic 
review and 
meta-analysis 
Descriptive 
study 
Population-based cohort studies 
Data sources Existing 
literature 
Swedish 
Prescribed 
Drug Registry 
Swedish Prescribed Drug Registry, 
Cancer Registry, Patient Registry, 
and Causes of Death Registry  
Participants Individuals 
receiving 
Helicobacter 
pylori 
eradication 
treatment 
Swedish residents aged ≥18 years receiving 
Helicobacter pylori eradication treatment 
Study period Until 10 
November 2015 
1 July 2005 – 
31 December 
2014 
1 July 2005 – 31 December 2012 
Exposure Helicobacter pylori eradication treatment 
Outcome Gastric and 
oesophageal 
cancer, MALT 
lymphoma 
Not applicable Gastric 
adenocarcinoma 
Oesophageal 
adenocarcinoma, 
oesophageal 
squamous cell 
carcinoma, and 
Barrett’s 
oesophagus 
Confounders As assessed in 
included studies 
Not applicable Age, sex, calendar period, and 
place of residence 
Statistical 
analysis 
Random effects 
meta-analysis 
Frequency 
calculations 
Standardised incidence ratios 
 11 
4.1 DATA SOURCES 
4.1.1 Published literature 
The data source in Study I was published literature available from PubMed, Embase, Web of 
Science or the Cochrane Library.   
4.1.2 The Swedish Prescribed Drug Registry 
This registry started on 1 July 2005 and contains information on almost all prescribed and 
dispensed drugs for Swedish residents. The registry contains information on some patient 
characteristics, i.e. age, sex, and place of residence; the medication itself including name, 
Anatomical Therapeutic Chemical (ATC) code, dosage, and drug package size; the 
prescriptions including the prescribed amount, dates of prescription and dispensing; the costs; 
and information about the practice issuing the prescription including the prescribers’ 
profession and medical specialty. Prescriptions given only during in-hospitalisations and 
over-the-counter medications are not recorded. Indications for prescriptions as well as the 
exact prescribed daily dose and duration are not available. Instead dosages and durations are 
available as defined daily dose (DDD) per package. A company that provides nationwide 
pharmaceutical services, the National Corporation of Swedish Pharmacies, transfers 
information on all dispensed prescriptions to the Swedish National Board of Health and 
Welfare once per month. The latter is responsible for the holding and management of the 
registry. The registry is virtually complete for the whole Swedish population with patient 
identifying data missing in less than 0.3% of all records.(67) This registry was linked to other 
registries using the personal identity number that is given to each Swedish resident upon birth 
or immigration and used throughout life. Personal identity numbers are replaced with code 
numbers by the National Board of Health and Welfare before data is sent out, to ensure 
anonymity of the patients.    
4.1.3 The Swedish Cancer Registry 
This registry was established in 1958 and contains information on malignant cancers for all 
Swedish residents. Recorded information includes the patients’ personal identity number, sex, 
place of residence at diagnosis, reporting hospital and department, date of diagnosis, clinical 
and histological cancer type, and tumour stage at diagnosis. The registry has an at least 96% 
complete registration of the type and date of diagnosis of all cancers in Sweden since 1961. 
The completeness of the recording is 98% for non-cardia gastric adenocarcinoma as well as 
for oesophageal cancer.(68, 69)   
4.1.4 The Swedish Patient Registry 
This registry is comprised of three separate registries. The Swedish Inpatient Registry, which 
is nationwide complete since 1987 and contains information on in-hospital stays; the Swedish 
Day Surgery Registry which was added in 1997; and the Swedish Outpatient Registry, which 
contains information on patients visiting an outpatient clinic from 2001. The registry does not 
hold information on primary health care and visits where no medical doctor was involved. 
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Recorded information includes the patients’ age, diagnoses recorded according to the 
International Classification of Diseases (ICD), date of visit or admission to hospital, 
discharge date, operation codes and dates, and information on the clinic.   
4.1.5 The Swedish Causes of Death Registry 
This registry contains data on all deaths in Sweden since 1961. Until 2011 only deaths among 
Swedish residents, occurring both in Sweden and abroad, were recorded. From 2012 the 
registry also includes deaths that occurred in Sweden among non-Swedish residents. 
Registration of death dates is essentially 100% complete. The cause of death is recorded 
according to the international version of the ICD. Around 0.5% of deaths do not have a 
recorded cause of death.  
4.2 STUDY I 
4.2.1 Design 
This was a systematic review and meta-analysis following the PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses) guidelines. The study aimed to assess the 
risk of gastric cancer, oesophageal cancer and MALT lymphoma after eradication treatment 
for Helicobacter pylori.  
The exposure was eradication treatment for Helicobacter pylori using any antibiotic regimen 
with the intention of eradicating this bacterium. The risk of the outcomes gastric cancer, 
oesophageal cancer or MALT lymphoma had to be compared to either non-eradicated or 
unsuccessfully eradicated individuals.  
The literature was searched in PubMed, Embase, Web of Science and the Cochrane Library 
until November 2015, using four search blocks. The first block consisted of the term 
“Helicobacter pylori” and synonyms. The second block covered “eradication” and included 
generic medication names for antibiotics and proton pump inhibitors. A third block consisted 
of either “gastric” or “oesophageal” and synonyms. The fourth block included “cancer” and 
synonyms as well as the histological cancer types. Searches for gastric and oesophageal were 
conducted separately from each other. There were no specific restrictions regarding the 
search. Backwards and forwards citation tracking was applied to the included articles to 
identify other possible relevant studies.  
The retrieved articles were first evaluated based on titles by the author, after which the 
selection based on abstracts and full text was performed by both the author and the principal 
supervisor independently. Any disagreement was solved by consensus. Exclusion criteria 
were animal studies, studies without original data, meeting abstracts, case reports and case-
control studies. Authors of articles were contacted in an attempt to retrieve the number of 
cancer cases found in comparison groups. For studies based on the same study population, the 
most recent article with the longest follow-up time was included.  
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Extracted data from the studies included cancer cases in the treatment and control groups, 
adjusted relative risks (if reported), geographical location, method to detect Helicobacter 
pylori, Helicobacter pylori eradication regimen, success of eradication, age (mean and range), 
sex ratio, follow-up time, and the histological type of the cancer. The quality of the studies 
was assessed using the Newcastle Ottawa scale.(70) This tool includes items on the 
representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment 
of the exposure, demonstration that the outcome of interest was not present at the onset of the 
study, comparability of study cohorts on the basis of the design or analysis, assessment of 
outcome, length and adequacy of the follow-up of the cohorts. From a maximum of 9 points, 
studies that scored below 4 were deemed to be of low quality, 4 and 5 of moderate quality, 
and above 5 of high quality. The data extraction and quality assessment were performed 
independently by the author and the principal supervisor.  
4.2.2 Statistical analysis 
A random effects model was used for the meta-analysis, to take heterogeneity between 
studies into account. To assess the risk of cancer development, the cancer risk in individuals 
receiving Helicobacter pylori eradication treatment was compared to the risk in those with no 
eradication or unsuccessful eradication and expressed as unadjusted risk ratios (RRs) with 
95% CIs. A second analysis included the studies reporting adjusted relative risks and their 
95% CIs, grouped by Cox or Poisson models, taking follow-up time into account. Subgroup 
analyses were performed for baseline gastric histology (atrophic gastritis or intestinal 
metaplasia versus not reported), and type of control group (eradicated versus non-
eradicated, or successful versus unsuccessful eradication). Heterogeneity was assessed 
using the I2 statistic, defining an I2 of greater than 50% as a substantial degree of 
heterogeneity.(71) Cochran’s Q test was used to assess the statistical significance of 
heterogeneity, with values smaller than 0.10 representing substantial heterogeneity. 
Publication bias was assessed using a funnel plot and Egger’s test, where a P-value of 
>0.05 indicated no evidence for this bias. All statistical tests were two-sided.  
4.3 STUDY II 
4.3.1 Design 
This descriptive study presents the use of Helicobacter pylori eradication treatment in 
Sweden from 1 July 2005 until 31 December 2014. The Swedish Prescribed Drug Registry 
was used for information on patients’ age and sex, ATC codes for antibiotics and drugs for 
peptic ulcers and gastro-oesophageal reflux disease, DDD per package, and dates of 
dispensing. An eradication episode for Helicobacter pylori was a priori defined as a 
combination of prescriptions of at least two different antibiotics dispensed on the same date. 
A PPI had to be prescribed from 60 days before to 5 days after the antibiotics. This time 
window was used to include individuals already using PPIs, as well as to take temporary non-
availability in the pharmacy into account. Prescription episodes including antibiotics with a 
dosage for >21 days (according to the DDD), and individuals who received ≥50 prescriptions 
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for antibiotics during the study period were excluded to avoid including treatment indications 
other than Helicobacter pylori eradication. Three different prescription combinations were 
included as eradication regimens: 1) The recommended eradication regimen in Sweden using 
a combination package (A02BD06) containing esomeprazole, amoxicillin and 
clarithromycin; 2) the recommended eradication regimen prescribed as separate drugs (at 
least two antibiotics) consisting of amoxicillin (J01CA04) and/or clarithromycin (J01FA09) 
and/or metronidazole (J01XD01) in combination with a PPI (A02BC). To be considered a 
recommended regimen, no other antibiotics were to be prescribed at the same time; 3) 
alternative eradication regimens consisting of a PPI in combination with two or more 
antibiotics of which at least one was from the following groups (excluding the above 
mentioned recommended antibiotics): macrolides (J01FA), imidazole derivatives (J01XD), 
tetracyclines (J01AA), fluoroquinolones (J01MA), nitrofuran derivatives (J01XE) or rifabutin 
(J04AB04), possibly in combination with bismuth subcitrate (A02BX05).  
4.3.2 Statistical analysis 
Absolute and relative frequencies of the different eradication regimens and individual 
antibiotics were calculated and stratified by age group (10-year intervals), sex, and calendar 
year. The first eradication treatment in each individual during the study period was analysed 
separately from second and third eradication episodes. Fourth or any subsequent eradication 
episodes in one individual were not included in this study to assure validity, e.g. that the 
treatment was administered as intended. Prescription trends over time were assessed by 
dividing all prescriptions in one year by number of inhabitants in Sweden for the same year, 
thus calculating the incidence proportion for each calendar year from 2006 onwards.  
4.4 STUDY III AND IV 
4.4.1 Design 
These population-based, nationwide, Swedish cohort studies included all individuals who 
received at least one prescription and dispensing of Helicobacter pylori eradication treatment 
with a recommended regimen during 1 July 2005 to 31 December 2012, as assessed in Study 
II. The cancer outcomes were obtained from the Swedish Cancer Registry, and these were 
gastric adenocarcinoma, non-cardia gastric adenocarcinoma and cardia adenocarcinoma in 
Study III, and oesophageal adenocarcinoma and squamous cell carcinoma in Study IV. Study 
IV also included Barrett’s oesophagus, assessed from the Swedish Patient Registry. The 
outcomes had to be the first in each individual and only primary cancers were included. 
Similarly, patients with Barrett’s oesophagus were eligible only if they had no history of 
cancer. Diagnoses occurring within one year of the eradication treatment were excluded to 
avoid detection bias. The included codes from the ICD version 7 (ICD7) were 151 (gastric 
cancer), 151.0 (non-cardia gastric cancer), 151.1 (cardia cancer), 151.8 (multifocal gastric 
cancer), and 151.9 (gastric cancer, not further specified) for gastric cancer; 150 (oesophageal 
cancer), 150.0 (oesophageal cancer, all parts), 150.8 (multifocal oesophageal cancer), and 
150.9 (oesophageal cancer, not further specified) for oesophageal cancer; and K22.7 for 
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Barrett’s oesophagus from the ICD10. The histological code 096 from the C24 WHO 
classification of histology defined adenocarcinoma, and the code 146 defined squamous cell 
carcinoma. The possible confounders adjusted for by standardisation were age (categorised 
into age groups 18-59, 60-69 or ≥70 years), sex (men or women) and calendar period (2005-
2006, 2007-2009 or 2010-2012). Confounding by place of residence (urban or rural) was 
assessed from the Swedish Prescribed Drug Registry because of its correlation with 
socioeconomic and lifestyle factors.(72)  
4.4.2 Statistical analysis 
Standardised incidence ratios (SIRs) with 95% CIs were calculated by dividing the observed 
number of cases in the eradication cohort by the expected number of cases derived from the 
Swedish general population of the same sex, age and calendar period with the categorisation 
presented above. To calculate the exact number of person-years of follow-up in each stratum, 
Clayton’s algorithm was used, where follow-up started from the date of the first dispensed 
prescription for eradication of Helicobacter pylori.(73) An additional analysis was performed 
which started from the last dispensed prescription of eradication treatment. Follow-up 
continued until the occurrence of any cancer, death, or the end of the study period (31 
December 2012), whichever came first. For Barrett’s oesophagus follow-up ended at the first 
date of a Barrett’s diagnosis, in addition to the criteria listed above. Subgroup analyses were 
performed for time after eradication (grouped into 1-2, 3-4 or 5-7.5 years) and number of 
dispensed eradication treatments (1, 2 or >2). Multiple eradication treatments indicated that 
an individual was infected with Helicobacter pylori for a prolonged amount of time. In Study 
III additional subgroup analyses evaluated the risk of cancer in individuals with peptic ulcer 
(gastric or duodenal), and gastritis (chronic or atrophic). Poisson regression was used to 
analyse the influence of length of follow-up and potential confounding by place of residence 
(urban or rural), yielding incidence rate ratios (IRRs) with 95% CIs.  
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5 RESULTS 
5.1 STUDY I 
Of the 3629 articles identified in the systematic database searches, eight cohort studies 
assessing the risk of gastric cancer after Helicobacter pylori eradication were included in the 
systematic review and meta-analysis (Figure 4). There was only one study assessing the risk 
of oesophageal cancer, and no study assessed the risk of MALT lymphoma. Randomised 
controlled trials (RCTs) were excluded because a previously published meta-analysis 
included all identified RCTs.(4)  
Of the included studies, seven were conducted in Japan and one in Finland. Two of the 
Japanese studies included 98% and 89% men.(74, 75) The largest study had 3650 individuals 
receiving eradication treatment and 11,628 individuals as control group. The same study also 
had the longest follow-up time of all included studies with a maximum of 20 years.(76) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Study selection for a systematic review and meta-analysis of studies assessing gastric cancer 
risk after Helicobacter pylori eradication. 
Articles identified through database searches 
(PubMed, Web of Science, Embase,  
Cochrane Library) 
(n=4729) 
Additional articles identified through 
citation tracking 
(n=1) 
Articles after duplicates removed 
(n=3629) 
Articles excluded based on title and 
abstract  
(n=3591) 
Full-text articles assessed for 
eligibility 
(n=38) 
Full-text articles excluded, 
with reasons: 
 Randomised clinical trials 
(n=9) 
 Case-control study (n=1) 
 Comment (n=3) 
 Exposure of antibiotic use 
(n=1) 
 Unclear study (n=1) 
 No new data/review (n=3) 
 No outcomes yet (n=1) 
 Conference abstract (n=1) 
 No suitable control group 
(n=7) 
 Data on same population 
(n=3) 
Articles included in 
qualitative and quantitative 
synthesis 
(n=8) 
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Gastric cancer developed in 119 (0.9%) out of 12,899 patients receiving eradication 
treatment, and in 208 out of 18,654 (1.1%) unsuccessfully treated or non-eradicated patients. 
Meta-analysis of the eight included studies yielded a RR of 0.46 (95% CI 0.32-0.66) 
favouring eradication treatment (Figure 5). Analysis of the five studies comparing successful 
to unsuccessful eradication provided a RR of 0.47 (95% CI 0.31-0.71), while the three studies 
comparing eradicated to non-eradicated individuals provided a RR of 0.39 (95% CI 0.14-
1.08) (Figure 5).  
 
Figure 5. Forest plot of studies assessing gastric cancer risk after Helicobacter pylori eradication 
comparing eradicated to non-eradicated individuals, and successful to unsuccessful eradication.  
 
In a Chinese RCT assessing oesophageal cancer risk, two out of 817 (0.2%) eradicated 
individuals developed oesophageal squamous cell carcinoma, while one out of 813 (0.1%) 
individuals receiving placebo developed this cancer type.  
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5.2 STUDY II 
In Sweden, a total of 157,915 prescriptions for Helicobacter pylori eradication were 
dispensed to 140,391 individuals (1.5% of the Swedish population) during July 2005 to 
December 2014. The largest part (127,810 individuals, 91.0%) received one eradication, 9900 
(7.1%) received two eradications, 1669 (1.2%) received three eradications, and 1012 (0.1%) 
received four or more eradications. In most cases (95.3%) a PPI was prescribed on the same 
day as the antibiotics. The recommended regimen was prescribed in 95.4% of all 
eradications. From 2006 to 2014 the dispensed prescriptions of the recommended eradication 
regimen decreased from 193 to 148 per 100,000 residents (Figure 6). Even during second and 
third eradications, the recommended regimen was used in 92.7% of eradications (this was 
95.8% during first eradications) (Table 2). Although used in few cases, the most common 
combinations for an alternative eradication regimen were amoxicillin and ciprofloxacin 
(1.3%), and amoxicillin and doxycycline (0.5%) (Table 2). 
 
Figure 6. Incidence of Helicobacter pylori eradication over time in Sweden per 100,000 residents.  
Table 2. Use of the most often prescribed combinations of antibiotics and individual antibiotics for 
Helicobacter pylori eradication. 
 
First 
eradication 
Second/third 
eradication Total (n, %) 
Total 140,391 (100) 15,262 (100) 157,915 (100) 
Combinations    
Combination package 119,152 (84.9) 13,022 (85.3) 134,079 (84.9) 
Amoxicillin + clarithromycin 15,342 (10.9) 1143 (7.5) 16,553 (10.5) 
Amoxicillin + doxycycline 643 (0.5) 160 (1.0) 834 (0.5) 
Amoxicillin + ciprofloxacin 1739 (1.2) 286 (1.9) 2118 (1.3) 
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5.3 STUDY III AND IV 
Participants 
The study cohort included 95,176 individuals receiving at least one prescription for 
Helicobacter pylori eradication treatment during the study period 2005-2012. Slightly more 
than half of the participants were women (53.7%) and the largest part resided in urban areas 
(74.6%) (Table 3). During 351,018 person-years of follow-up, with a mean of 3.7 and a 
maximum of 7.5 years, 75 (0.08%) individuals developed gastric adenocarcinoma. Of these, 
69 (0.07%) were non-cardia adenocarcinomas, and 6 (0.01%) were cardia adenocarcinomas. 
Gastric adenocarcinoma developed in 3 out of 732 (0.4%) individuals with gastric ulcer, 
while none of the 1235 individuals with duodenal ulcer was diagnosed with this cancer type. 
Gastric adenocarcinoma developed in 2 out of 1898 (0.1%) individuals with chronic or 
atrophic gastritis. Oesophageal adenocarcinoma developed in 11 (0.01%) individuals, and 
oesophageal squamous cell carcinoma in 10 (0.01%) individuals. Barrett’s oesophagus 
developed in 178 out of 95,013 individuals (0.19%) during a follow-up time of 349,759 
person-years (Table 3). This cohort included fewer individuals because those diagnosed with 
Barrett’s oesophagus before a first eradication treatment were excluded.  
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Table 3. Descriptive characteristics of study participants receiving eradication treatment for 
Helicobacter pylori in Sweden during 2005-2012. 
Characteristic 
 
Participants 
Number (%) 
Total 95,176 (100.0) 
Sex 
 
Men 44,028 (46.3) 
Women 51,148 (53.7) 
Age (years) 
 
18-59 57,214 (60.1) 
60-69 17,808 (18.7) 
≥70 20,154 (21.2) 
Calendar period at entry 
 
2005-2006 21,218 (22.3) 
2007-2009 38,573 (40.5) 
2010-2012 35,385 (37.2) 
Place of residence 
 
Rural 23,686 (24.9) 
Urban 71,032 (74.6) 
Missing 458 (0.5) 
Gastric cancer 
All gastric adenocarcinoma 
Non-cardia gastric adenocarcinoma 
Cardia adenocarcinoma 
 
75 (0.08) 
69 (0.07) 
6 (0.01) 
Oesophageal cancer  
Oesophageal adenocarcinoma 11 (0.01) 
Oesophageal squamous cell carcinoma 10 (0.01) 
Follow-up (years) for cancer 
 
Total 351,018 
Mean 3.7 
Barrett’s oesophagus (out of 95,013 individuals) 178 (0.19) 
Follow-up (years) for Barrett's oesophagus 
 
Total 349,759 
Mean 3.7 
 
Gastric adenocarcinoma 
The overall risk of gastric adenocarcinoma decreased over time after eradication treatment, 
with SIRs of 8.65 (95% CI 6.37-11.46) 1-2 years, 2.02 (95% CI 1.25-3.09) 3-4 years, and 
0.31 (95% CI 0.11-0.67) 5-7.5 years after eradication treatment (Table 4). Analysis starting 
from the last eradication treatment showed a similar trend. The risk of gastric 
adenocarcinoma was increased for those with a higher number of eradication treatments. The 
SIR was 1.88 (95% CI 1.44-2.41) in individuals with one eradication treatment, and 7.44 
(95% CI 2.72-16.19) in those with more than 2 eradication treatments. There was no 
difference in gastric adenocarcinoma risk between individuals residing in rural or urban areas 
(IRR 0.98, 95% CI 0.59-1.61) (Table 4).  
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The risk of non-cardia gastric adenocarcinoma also decreased over time after eradication, and 
the risk increased by number of eradication treatments. The trends were similar to those for 
all gastric adenocarcinoma, but with wider CIs (Table 4).   
For cardia adenocarcinoma there were too few cases to allow analysis over time after 
eradication and by number of eradications, but the overall SIR was 0.60 (95% CI 0.22-1.30) 
(Table 4).  
Oesophageal cancer 
The risk of oesophageal adenocarcinoma decreased over time after eradication treatment, 
from SIR 3.31 (95% CI 1.21-7.20) 1-2 years to 0.17 (95% CI 0.00-0.92) 5-7.5 years after 
eradication treatment (Table 4). Ten of the 11 cases were found in individuals receiving one 
eradication treatment, thus a risk assessment by number of eradications was not possible. 
Place of residence did not influence the risk (IRR 4.43, 95% CI 0.57-34.70).  
For oesophageal squamous cell carcinoma, five cases were detected during 1-2 years after 
eradication, another five cases 3-4 years after eradication, and no cases 5-7.5 years after 
eradication (Table 4). The SIR showed a decreasing trend, which was confirmed by Poisson 
regression yielding an IRR of 0.07 (95% CI 0.02-0.28) for 3-4 years after eradication, 
compared to 1-2 years after eradication. Nine of the 10 cases occurred in individuals 
receiving one eradication treatment, and there was no influence of place of residence on the 
outcome (IRR 0.94, 95% CI 0.24-3.66) (Table 4).  
The SIRs of Barrett’s oesophagus also decreased over time after eradication treatment, from 
10.96 (95% CI 8.95-13.28) at 1-2 years, to 2.72 (95% CI 2.02-3.59) 3-4 years, and 0.71 (95% 
CI 0.45-1.05) at 5-7.5 years after eradication (Table 4), although Poisson regression was non-
significant with an IRR of 1.00 (95% CI 0.40-2.49) 5-7.5 years after eradication treatment. 
An increased risk was seen in individuals with 2 and more than 2 eradication treatments with 
SIRs of 2.50 (95% CI 2.10-2.95) in individuals with 1 eradication treatment, 5.83 (95% CI 
3.93-8.33) in those with 2 eradication treatments, and 4.51 (95% CI 1.81-9.29) in those with 
more than 2 eradication treatments. There appeared to be a trend towards a risk decrease for 
individuals residing in urban areas (IRR 0.75, 95% CI 0.54-1.02).   
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                 Table 4. The risk of gastric and oesophageal cancer and Barrett’s oesophagus after eradication treatment for Helicobacter pylori.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 SIR, standardised incidence ratio. CI, confidence interval. NA, not applicable.
Gastric tumours 
  Gastric adenocarcinoma Non-cardia gastric adenocarcinoma Cardia adenocarcinoma 
  Number of cases SIR (95% CI) Number of cases SIR (95% CI) Number of cases SIR (95% CI) 
Total 75 2.08 (1.63-2.60) 69 2.64 (2.06-3.35) 6 0.60 (0.22-1.30) 
Follow-up 
time, years 
       
1-2 48 8.65 (6.37-11.46) 43 10.74 (7.77-14.46) 5 3.23 (1.04-7.54) 
3-4 21 2.02 (1.25-3.09) 20 2.67 (1.63-4.13) 1 0.35 (0.01-1.93) 
5-7.5 6 0.31 (0.11-0.67) 6 0.43 (0.16-0.93) 0 NA 
Number of 
eradications 
       
1 61 1.88 (1.44-2.41) 56 2.38 (1.80-3.10) 5 0.56 (0.18-1.30) 
2 8 2.84 (1.22-5.59) 7 3.45 (1.38-7.11) 1 1.26 (0.02-7.02) 
>2 6 7.44 (2.72-16.19) 6 10.47 (3.82-22.78) 0 NA 
Oesophageal tumours 
  Barrett’s oesophagus Oesophageal adenocarcinoma Oesophageal squamous cell carcinoma 
  Number of cases SIR (95% CI) Number of cases SIR (95% CI) Number of cases SIR (95% CI) 
Total 178 2.82 (2.42-3.26) 11 0.96 (0.48-1.72) 10 1.24 (0.59-2.28) 
Follow-up 
time, years 
        
1-2 104 10.96 (8.95-13.28) 6 3.31 (1.21-7.20) 5 4.08 (1.32-9.53) 
3-4 50 2.72 (2.02-3.59) 4 1.20 (0.32-3.08) 5 2.17 (0.70-5.06) 
5-7.5 24 0.71 (0.45-1.05) 1 0.17 (0.00-0.92) 0 NA 
Number of 
eradications 
        
1 141 2.50 (2.10-2.95) 10 0.97 (0.47-1.79) 9 1.24 (0.57-2.36) 
2 30 5.83 (3.93-8.33) 1 1.12 (0.02-6.25) 0 NA 
>2 6 4.51 (1.81-9.29) 0 NA 1 5.34 (0.07-29.71) 
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6 METHODOLOGICAL CONSIDERATIONS 
6.1 STUDY DESIGN 
The study designs in this thesis include a systematic review and meta-analysis (Study I), a 
descriptive study (Study II) and two cohort studies (Study III and IV).  
Epidemiological studies are commonly divided in experimental and observational studies. 
Well-designed experimental studies like RCTs are usually seen as having the strongest level 
of evidence, since the design of the study minimises the risk of bias if the sample size is 
sufficient and the study is well conducted. In these experimental studies, the researchers 
appoint the exposure to study participants. However, many research questions do not allow 
for an experimental study, because this can be unethical or infeasible. The studies in this 
thesis (Study III and IV) are conducted with an observational design, since at least in Sweden 
an experimental design would be unethical. Individuals are tested for Helicobacter pylori in 
case of peptic ulcer disease, early gastric cancer, MALT lymphoma or when experiencing 
dyspepsia without any alarm symptoms. In these cases, a diagnosis of Helicobacter pylori 
requires treatment, and it would be unethical to be left untreated. Furthermore, the availability 
of large, nationwide datasets in Sweden makes an observational design more feasible. 
Observational studies are often also more representative of actual clinical practice and the 
findings are more generalisable, because there are no strict inclusion criteria like in RCTs, 
making the study population more similar to the population seen in everyday clinical practice. 
The researchers observe individuals with different exposures and evaluate if they develop the 
outcome of interest or not. The main types of observational studies are cohort studies, case-
control studies, and cross-sectional studies which assess associations on an individual level, 
and ecologic studies where associations are assessed on group level. Cohort studies are 
usually preferred over case-control studies, because they have a lower risk of recall bias and 
selection bias, and can use the entire source population. Cohort studies can become very 
expensive and time-consuming when all the data have yet to be collected. However, with the 
availability of the Swedish health care registries this problem can be solved.   
In cohort studies the study participants are grouped by exposure status and followed over 
time to observe if they develop the outcome of interest. In Study III and IV the cohort was 
assembled from individuals exposed to Helicobacter pylori eradication. The unexposed group 
was the general population of Sweden, and it was assumed they (at least the vast majority) 
did not receive eradication treatment. This cannot be ascertained completely, since the 
Swedish Prescribed Drug Registry did not start until July 2005. In the cohort studies the 
exposure data were recorded in the registries before the outcome occurred, which counteracts 
bias. The outcome was already known at the start date of the studies (making the studies in 
some sense “retrospective”, although the data collection itself was prospective), but this could 
not have affected the exposure classification because this was already recorded. However, 
different definitions are in use to define prospective and retrospective studies, and a more 
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present-day definition would recommend the term “prospective” when the outcome could not 
have influenced exposure information. 
A descriptive study (Study II) was conducted in order to better understand the current clinical 
practice in Sweden regarding eradication treatment for Helicobacter pylori and analyse the 
trend over a recent decade. This study was based on the entire Swedish population and could 
thus provide unselected information representative of the Swedish population.  
A systematic review and meta-analysis (Study I) is supposed to present the current 
knowledge in an unbiased manner by systematically searching several databases. Meta-
analysis provides the opportunity to quantify the effect size based on several relevant studies 
and could give a more robust estimate than each individual study by increasing the sample 
size. By putting together all relevant existing information, this study was also used to 
highlight a knowledge gap, leading on to Studies III and IV.  
6.2 INTERNAL VALIDITY 
There are three main types of systematic errors that threaten the internal validity of 
epidemiologic studies; selection bias, information bias and confounding.  
6.2.1 Selection bias 
This type of bias arises when study participants are not representative of the population that 
was intended to be studied. This could happen for example if study participants choose to 
consult a clinician because someone in their family has gastric cancer, and therefore are more 
likely to be tested for Helicobacter pylori, and consequently receive eradication. The 
participants would then have a higher risk of developing gastric cancer compared to the 
general population, possibly due to genetic factors, and they might also be more likely to 
receive Helicobacter pylori eradication treatment (exposure) even with mild symptoms, since 
infection with the bacterium mostly occurs within families.(77) The main issue with selection 
bias is that the relation between exposure and outcome cannot be studied the way it was 
intended, and the results of the study will not depict the true causal effect. Studies II-IV were 
based on nationwide registries with procedural registration of the information, including the 
exposure and outcomes (for Study III and IV) of these studies. The comparison group was the 
Swedish general population. This way of selecting study participants has minimised the risk 
of selection bias.  
6.2.2 Information bias 
This bias arises when the exposure or outcome is not measured correctly, and thus is not 
classified in the right category. In Studies III and IV there is a possibility of misclassification 
of the exposure. Individuals could have received the combination of drugs for another 
indication than Helicobacter pylori eradication. However, this misclassification was limited 
by only including the recommended eradication regimen as exposure, which in around 85% 
of cases was prescribed using the Helicobacter pylori eradication package as described in 
Study II. If individuals did receive the drugs for another indication, the treatment will most 
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likely still have eradicated the bacterium, if present. The Swedish general population 
(unexposed group) did contain the participants who received eradication treatment. This is 
unlikely to have had major influence on the results, since the studied cohort only represents 
only 1.3% of the population. Any influence would have diluted the associations towards the 
null. Cancer outcomes could have been misclassified in the Cancer Registry, especially 
oesophageal adenocarcinomas and cardia adenocarcinomas, because the distinction between 
these two is not always clear.(69) This misclassification occurs independent of the exposure 
status and other variables in the study, and is therefore non-differential with possible bias 
towards the null. Another misclassification of cancer could have occurred if the diagnosis 
was not reported to the Cancer Registry. However, this registry has a 98% completeness for 
both gastric and oesophageal cancer, and thus the risk of misclassification was small.(68, 69) 
Detection bias could have occurred if the cancer is diagnosed earlier in individuals that 
received eradication treatment, because they are under surveillance or they more readily 
contact a doctor given their medical history. This would have been a differential 
misclassification, however it is unlikely to have influence the results since the exposed 
individuals were also part of the general population, and the majority of the general 
population in Sweden was never infected with Helicobacter pylori and thus does not carry an 
increased risk of gastric cancer.   
6.2.3 Confounding 
A confounder is a variable that influences both the exposure and the outcome and does not lie 
on the causal pathway. Studies III and IV adjusted for some potential confounders like age, 
sex and calendar period. Another possible confounder is socioeconomic status, which 
influence was assessed by a proxy variable place of residence. Because of the design, there is 
always a possibility of residual confounding in observational studies, here for example by 
dietary factors, genetic factors, smoking or obesity. These possible confounders could not be 
assessed from the registries since they are not collected regularly on a nationwide level.  
6.3 PRECISION 
Precision can be seen as the opposite of random error, meaning that with a large precision and 
increasing power, there is less random error in a study. An approach to random error is 
needed to examine if the results of a study can be explained by chance alone. This can be 
done by hypothesis testing, which estimates the likelihood that the null hypothesis is true. 
The null hypothesis is the hypothesis that there is no association between the exposure and 
outcome under study. This can be estimated by 95% CIs and P-values. The level of the P-
value is usually set at 0.05, which means that if P is smaller than this value there is a less than 
5% chance that the null hypothesis is true. This is known as a statistically significant 
association. However, the P-value does not give much information on the precision of this 
association. Therefore 95% CIs were used in Studies I, III and IV, where it is possible to test 
if the association was significant (if the CI did not include 1) and at the same time the 
precision can be estimated from how wide the CI is. The precision can be increased by 
increasing the sample size of the study. In Study I the 95% CI was narrow, since the sample 
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size was large by adding multiple studies together in a meta-analysis. In Studies III and IV 
some of the 95% CIs from the subgroup analyses are relatively wide. However, the 95% CIs 
were narrow for the overall analyses per cancer type and the subgroup with the longest 
follow-up on account of the large number of person-years included in the analyses, indicating 
sufficient precision.     
6.4 EXTERNAL VALIDITY 
The external validity of a study is also called generalisability, which concerns whether the 
results of a study are applicable to other populations than the one that was studied. 
Generalisability should only be assessed if the internal validity of the study is good. In Study 
I all of the included studies were conducted in Japan, except for one study from Finland.(76) 
It was therefore decided that the results of this study were not generalisable to the Swedish 
population, which identified the need for further studies on this topic, leading to Study III. 
The results of Studies III and IV are at least generalisable to the whole Swedish population, 
because they were based on nationwide registries. It can be argued that these results are even 
applicable in populations with a similar low prevalence of Helicobacter pylori and low 
prevalence of antibiotic resistance, and similar incidences of gastric and oesophageal 
adenocarcinomas, for example other Scandinavian countries. Study II was conducted to 
visualise the use of Helicobacter pylori eradication treatment in Sweden and can therefore not 
be generalised to other populations. However, the findings may be generalisable to 
populations with similar characteristics to that of the Swedish population and similar 
treatment regimens for Helicobacter pylori eradication.    
6.5 SYSTEMATIC REVIEWS AND META-ANALYSES 
Meta-analyses are conducted to quantify the results of multiple earlier studies, and provide a 
more robust estimate by increasing the sample size. A meta-analysis cannot be conducted 
without a systematic review; a qualitative overview of the existing literature that is unbiased 
as to which studies are included, as opposed to narrative reviews. If these included studies are 
considered to be sufficiently homogeneous, a meta-analysis may be conducted. One of the 
biggest challenges with meta-analyses is though that there are possible sources of bias in each 
individual included study that cannot be entirely accounted for.  
When conducting a meta-analysis the search is the first step after completion of the study 
protocol. The search needs to be done in such a way that the risk of missing important articles 
is small, but that at the same time does not generate too many studies for feasibility. For this 
reason it is important to use multiple databases, and use several synonyms for the keywords 
in the search. Not all relevant studies may be found in these databases, and this issue is 
referred to as publication bias. Publication bias arises when not all studies in the field are 
published, most often due to negative results that did not show any association. Publication 
bias is sometimes also referred to as small study effects, because smaller studies more often 
lead to statistically non-significant results and will not be published. A way to assess 
publication bias is to construct a funnel plot, a scatterplot that shows the distribution of 
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studies according to their measured effect and size (indicated by the standard error). Visual 
inspection of this funnel plot will show publication bias if the studies are distributed 
unequally (asymmetrically) in the plot. Another way to assess publication bias is to use 
Egger’s test, a statistical test to assess the asymmetry of the funnel plot. However, this test 
has low power when less than ten studies are included.(71)    
Another issue that needs to be addressed in meta-analyses is heterogeneity. Analysis of 
heterogeneity describes the variability between the included studies. Heterogeneity may for 
example stem from differences in study design, study participants, or the way exposures and 
outcomes were assessed. In Study I a certain amount of heterogeneity was expected, since 
studies were conducted in different settings, and different regimens were used for 
Helicobacter pylori eradication. The analysis was therefore conducted using a random effects 
model. Heterogeneity can be measured with the I2 statistic, where a value of 0 to 40% 
represents low heterogeneity, 30 to 60% moderate heterogeneity, 50 to 90% substantial 
heterogeneity, and 75 to 100% represents considerable heterogeneity.(71) The statistical 
significance of heterogeneity may be assessed by Cochran’s Q test. However, this test has a 
low power when a low number of studies is included in the meta-analysis and the sample size 
in the studies is small.(71) Therefore a statistical significance level of 0.10 was chosen to 
determine heterogeneity in Study I. Another approach to heterogeneity is sensitivity analysis, 
where studies that are in some way different from the others are excluded to test the 
robustness of the results. In Study I several sensitivity analyses were conducted; one 
excluding the studies that did not adjust for confounding or follow-up time, one excluding the 
study that included individuals with intestinal metaplasia at baseline, and one excluding the 
study from Finland. All these sensitivity analyses yielded low to moderate heterogeneity. 
Heterogeneity may also be assessed using meta-regression, but this approach requires at least 
10 studies in the meta-analysis and was therefore not used in Study I.     
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7 GENERAL DISCUSSION 
7.1 STUDY I 
This systematic review and meta-analysis supports the hypothesis that Helicobacter pylori 
eradication treatment prevents gastric cancer.  
The meta-analysis was based on an a priori study protocol and was conducted according to 
the PRISMA guidelines. An inclusive search was performed in four databases, and there was 
no evidence of publication bias. The heterogeneity was low to moderate, which could 
partially be due to the inclusion of only cohort studies. Furthermore, these cohort studies 
better reflect the actual clinical situation, compared with RCTs. Although these studies carry 
a higher risk of bias, the study quality that was assessed using a recommended tool was found 
to be good in seven out of eight studies, while none of the studies was of low quality. A 
concern was the generalisability of the results to other populations, because almost all studies 
were conducted in Japan, a region with high prevalence of Helicobacter pylori and a high 
incidence of gastric cancer. 
A previous meta-analysis based on RCTs and a simultaneously published meta-analysis on 
both RCTs and cohort studies also showed a reduced risk of around 50% for gastric cancer 
after Helicobacter pylori eradication treatment,(4, 5) indicating consistency of the findings. 
The cohort studies included in the most recent study were largely the same as in the present 
meta-analysis, making these studies comparable regarding the characteristics of the included 
studies. In contrast, that similar meta-analysis analysed gastric cancer risk by different levels 
of baseline gastric cancer risk, concluding that the preventive effect of Helicobacter pylori 
eradication treatment is larger in populations with a higher baseline gastric cancer risk, which 
possibly contradicts the existence of a point-of-no-return in gastric cancer development 
according to the Correa pathway.(5, 78) 
In conclusion, this systematic review and meta-analysis suggests that Helicobacter pylori 
eradication treatment prevents the development of gastric cancer. There were not enough 
studies (only one) assessing the risk of oesophageal cancer after Helicobacter pylori 
eradication treatment to allow any evaluation of this risk in a meta-analysis.  
7.2 STUDY II 
This descriptive study based on the whole Swedish population showed that more than 95% of 
eradication treatments consisted of a recommended or standard eradication regimen. The 
incidence of Helicobacter pylori eradication treatment decreased during 2006-2014.  
This register-based study found that 91% of individuals ever receiving Helicobacter pylori 
eradication treatment only received one eradication episode. This number could be 
overestimated because no information was available before the start of the registry in July 
2005. Although the registry did not provide information on indications for treatment, it is 
likely that the recorded eradication episodes were given for Helicobacter pylori eradication, 
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since in nearly 85% of eradications the combination package was used, and a PPI was 
prescribed on the same day as the antibiotics in more than 95% of all eradication episodes. 
Some eradication episodes may still have been missed, among others because the ATC code 
used for metronidazole was the code for intravenous use (J01XD) and the code for oral use 
(P01AB01) was not available, since this was not classified as a systemic antibiotic (J01) but 
as an antiprotozoal (P01). Given that separate prescriptions of antibiotics for eradication were 
not very common, and that metronidazole is only recommended in case of penicillin allergy 
or clarithromycin resistance, this should only have had limited influence on the results. 
However, this does explain why almost no eradication episodes were found using 
metronidazole. There was no information about any eradication episodes taking place during 
hospitalisations, since the Drug Registry only records prescriptions picked up at a pharmacy, 
but this number should be very limited. In nearly 93% of second and third eradication 
episodes the recommended regimen was used again. This indicates that a sensitivity test for 
antibiotic resistance is rarely performed in clinical practice. Awareness is required regarding 
management of Helicobacter pylori eradication in Sweden, since repetition of the same 
regimen might not cure the patient and it could lead to increased antibiotic resistance in the 
population.  
During 1994-1996 a study described Helicobacter pylori eradication in a Danish 
population.(79) That study defined an eradication episode as a prescription of ulcer drugs 
(PPI or H2-receptor antagonist) in combination with one, two or three antibiotics on the same 
day. In that study, 86% of individuals had only one eradication episode. The incidence of 
eradication treatment was 220 per 100,000 inhabitants per year, compared to less than 200 
eradications per 100,000 inhabitants per year in the present study.(79) In contrast to Study II, 
the Danish study did not provide any description of recommended versus alternative 
eradication regimens.  
In conclusion, from July 2005 until December 2014 more than 140,000 individuals received 
Helicobacter pylori eradication treatment in Sweden. Eradication was mostly prescribed 
using a recommended regimen, also for secondary eradication episodes. Awareness needs to 
be raised regarding correct use of Helicobacter pylori eradication treatment in Sweden to 
prevent increase of antibiotic resistance and assure appropriate clinical treatment for 
individual patients.  
7.3 STUDY III 
This nationwide Swedish cohort study showed a decrease in risk of gastric adenocarcinoma 
from five years after Helicobacter pylori eradication treatment compared to the risk in the 
Swedish general population.  
This study is one of the first studies exploring the risk of gastric adenocarcinoma after 
Helicobacter pylori eradication treatment in a population with a low incidence of gastric 
cancer and low prevalence of Helicobacter pylori. Separate analyses were conducted for non-
cardia gastric adenocarcinoma which gives a more specific estimate of the studied 
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association, since Helicobacter pylori is not associated with an increased risk of cardia 
adenocarcinoma, but only of non-cardia gastric adenocarcinoma.(8) The follow-up of 7.5 
years was relatively short for cancer outcomes, but robust analyses were still possible due to 
the large sample size. Unfortunately, the registries do not contain information on success of 
the eradication treatment, which could mean that Helicobacter pylori was still present after 
treatment in some individuals, leading to a misclassification with probable dilution of effects 
when studying the per protocol treatment effect. The main results in this study were measured 
simulating an intention to treat protocol to emulate an RCT.(80) This was done to avoid 
unknown confounding because individuals who receive multiple eradications might have 
different characteristics than those who receive only one eradication.  
The decreased risk of gastric adenocarcinoma found in this study is in line with the only other 
cohort study assessing the association between Helicobacter pylori eradication and gastric 
cancer in a Western population, which was conducted in Finland.(76) That study also found a 
strong decrease in gastric cancer risk five years after eradication treatment in individuals who 
were successfully treated (SIR 0.14, 95% CI 0.00-0.75) and in those who lacked information 
on successful treatment (SIR 0.13, 95% CI 0.02-1.00), compared to Helicobacter pylori 
negative individuals. The results of the present study are also in line with the meta-analyses 
on RCTs and cohort studies, and with the meta-analysis in Study I, that all found a significant 
decrease in gastric cancer risk after eradication treatment for Helicobacter pylori.(4, 5) 
In conclusion, this study provides support for the hypothesis that eradication treatment for 
Helicobacter pylori prevents gastric adenocarcinoma also in countries with a low incidence 
of gastric cancer. This information can guide clinical decision-making for health care 
providers in these regions. This does not mean that widespread screening and eradication 
programs should be implemented, but it is instead recommended to follow the guidelines for 
indications to test for Helicobacter pylori and eradicate only when the test result is positive.    
7.4 STUDY IV 
This nationwide Swedish cohort study found a decreasing risk of oesophageal 
adenocarcinoma, Barrett’s oesophagus, and oesophageal squamous cell carcinoma over time 
after eradication treatment for Helicobacter pylori.  
During the study period, only 11 individuals were diagnosed with oesophageal 
adenocarcinoma, which makes it difficult to draw inferences because of the small number of 
cases. However, there were 178 cases of the premalignant condition Barrett’s oesophagus, 
and both the SIRs for oesophageal adenocarcinoma and Barrett’s oesophagus showed a 
decreasing risk over time after eradication treatment, which strengthens the study results.  
Based on previously published research that showed a decreased risk of oesophageal 
adenocarcinoma and Barrett’s oesophagus in individuals with Helicobacter pylori, the 
hypothesis for this study was that the risks of these conditions would instead increase after 
eradication treatment.(48, 49, 51, 52) However, in order for the risk of oesophageal 
adenocarcinoma to increase after eradication treatment the gastric atrophy caused by 
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Helicobacter pylori would need to be reversed. It is a possibility that gastric atrophy is not 
reversible, or that it would take many years to do so, explaining why no increased risk of 
oesophageal adenocarcinoma or Barrett’s oesophagus was found in the present study.  
The results of this study can counteract some of the concerns that eradication treatment for 
Helicobacter pylori would increase the risk of oesophageal adenocarcinoma, which could be 
a point of discussion especially in patients with risk factors for this cancer type, i.e. gastro-
oesophageal reflux and obesity. Therefore the recommendations for eradication treatment for 
Helicobacter pylori remain the same as in Study III; to eradicate after a positive test result 
based on a valid test indication. 
In conclusion, this was the first study assessing the risk of oesophageal adenocarcinoma and 
Barrett’s oesophagus after Helicobacter pylori eradication treatment. The results indicated a 
decreased risk of these conditions from five years and later after eradication treatment, which 
contradicted the hypothesis of an increased risk. This indicates that Helicobacter pylori 
eradication treatment should not be withheld in patients with a valid treatment indication.    
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8 CONCLUSIONS 
 Helicobacter pylori eradication treatment seems to prevent the development of gastric 
adenocarcinoma, both in settings with a low and high prevalence of Helicobacter 
pylori and low and high incidence of gastric cancer.  
 The risk of oesophageal adenocarcinoma and Barrett’s oesophagus does not seem to 
increase after eradication treatment for Helicobacter pylori, but may rather decrease.  
 Helicobacter pylori eradication treatment in Sweden mostly consists of the standard 
triple therapy regimen, even after a failed first eradication attempt.  
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9 FUTURE RESEARCH 
Although it might now seem clear that Helicobacter pylori eradication treatment decreases 
the risk of gastric adenocarcinoma, more research is needed to determine if there is a stage in 
the developmental pathway to gastric cancer, a so-called point of no return, where eradication 
treatment can no longer prevent gastric adenocarcinoma. This would require a large cohort 
study with gastric biopsies in different stages of development on the Correa pathway with a 
long follow-up duration.  
It is also still insufficiently clear why some people with Helicobacter pylori develop gastric 
cancer and the majority does not. Future research should focus on identifying individuals at 
an increased risk of developing gastric cancer, which can be for example targeted at bacterial 
characteristics or other aetiological factors that could enhance cancer development in 
combination with Helicobacter pylori.  
More and larger studies that examine the risk of oesophageal adenocarcinoma after 
Helicobacter pylori eradication are needed to validate our findings, and should be conducted 
in both regions with low and high incidence of oesophageal adenocarcinoma.  
Research should also aim at clarifying other potential harmful effects of Helicobacter pylori 
eradication treatment, for example increased antibiotic resistance due to unnecessary 
eradications and possible long-term changes in the human microbiome, especially in the 
stomach and gut, which pose a risk for a range of other conditions such as obesity and 
inflammatory diseases.  
Recent research has also highlighted that long-term use of PPIs could lead to an increased 
risk of gastric cancer. This is especially important in individuals with Helicobacter pylori, 
because they are already more prone to develop gastric atrophy. More research concerning 
the continued used of PPIs after Helicobacter pylori eradication is needed.  
Helicobacter pylori is possibly also associated with an increased risk of other gastrointestinal 
cancers, e.g. colorectal cancer, pancreatic cancer, and biliary tract cancer. More research is 
needed to confirm these associations and to examine the effect of eradication treatment on 
these outcomes.  
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10 POPULAR SCIENCE SUMMARY 
Helicobacter pylori: to treat or not to treat – that is the question 
Stomach cancer is included in the top 5 of most common cancers worldwide, and only a 
minority of people with this disease will survive more than 5 years after the diagnosis. The 
most important risk factor for stomach cancer is infection with the stomach bacterium 
Helicobacter pylori. Around half of all the people in the world have this bacterium. In 
Sweden, this rate is lower at about 20% of the population. Most often people get infected 
with the bacterium during childhood. Helicobacter pylori is transferred by people, probably 
partly due to sharing food and unhygienic living conditions. Because of the improvement in 
living circumstances in Sweden, the bacterium has become less common during recent 
decades. Helicobacter pylori can also cause stomach ulcers. Symptoms from ulcers 
commonly lead to detection and treatment of the bacterium. Treatment is called eradication 
and is given using a medicine that decreases acid production in the stomach (proton pump 
inhibitor) in combination with at least 2 antibiotics. However, only a small amount of people 
with Helicobacter pylori will get any disease from it, so it is not meaningful to test for the 
bacterium in all individuals and treat them. Treatment can however be an important approach 
to prevent stomach cancer. But more recently studies have shown that Helicobacter pylori 
infection can instead decrease the risk of oesophageal cancer, indicating a possibility that 
treatment can increase the risk of this cancer type. Oesophageal cancer has become more 
common during recent decades and is hard to cure. Therefore, the studies in this thesis try to 
answer the questions whether treatment of Helicobacter pylori actually reduces the risk of 
stomach cancer, and if it elevates the risk of oesophageal cancer. The aim was to provide 
scientific evidence to answer part of the question if Helicobacter pylori should be treated or 
not.  
Study I was based on a systematic review of published studies examining if treatment of 
Helicobacter pylori reduces the risk of stomach cancer. These studies were selected in a 
systematic way to ensure that all relevant studies were found. By putting together the results 
of several studies, the number of participants and cancer cases becomes larger, which makes 
the results more reliable. The 8 included studies, of which 7 were from Japan and 1 from 
Finland, showed that the risk of stomach cancer was around 50% lower after treatment of 
Helicobacter pylori.  
Study II was based on a nationwide Swedish health data registry (Prescribed Drug Registry) 
that collects information every time someone receives a doctor’s prescription for a medicine 
and picks it up at a pharmacy. The study described how the treatment for Helicobacter pylori 
is given in Sweden. In the period from July 2005 to December 2014 more than 140,000 
people had received eradication treatment, which equals 1.5% of the Swedish population. 
Most of these people (91%) got treated only once. The majority (95%) of treatments used the 
standard antibiotics that are recommended for this treatment. These standard antibiotics were 
also used in most second or third treatments.  
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Study III and IV included people from Study II who received eradication treatment. More 
information about these individuals was retrieved from other nationwide health data registries 
that collect information about cancers (Swedish Cancer Registry), other diseases and hospital 
stays (Swedish Patient Registry) and deaths (Swedish Causes of Death Registry). The risk of 
stomach cancer was higher in people who received eradication treatment compared to the 
stomach cancer risk in the rest of the comparable Swedish population. However, the risk went 
down over time and was around 70% lower from 5 years after the eradication treatment. For 
oesophageal cancer there were few cases, making the results less reliable. That is why the risk 
of Barrett’s oesophagus, a condition where the cells in the oesophagus change which may 
develop to oesophageal cancer, was also measured. Both the risk of oesophageal cancer and 
Barrett’s oesophagus seemed to decrease over time. The risk of Barrett’s oesophagus seemed 
to be lower than that of the general Swedish population from 5 years after eradication 
treatment.  
The conclusions that can be drawn from this thesis are that the treatment of Helicobacter 
pylori reduces the risk of stomach cancer. This was the case in both Asia and Sweden, 
although people from these parts of the world grow up and live in different circumstances. 
The risk of oesophageal cancer did not seem to be elevated after Helicobacter pylori 
eradication treatment. This means that Helicobacter pylori should probably be treated in all 
people that qualify for this treatment. There is a reason to believe that treatment can be 
improved in Sweden, by using different antibiotics if the treatment does not work the first 
time.      
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11 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Helicobacter pylori: att behandla eller inte behandla – det är frågan 
Magsäckscancer är bland de 5 mest vanligaste cancersjukdomar i världen, och det är många 
människor med sjukdomen som avlider inom 5 år efter att den har upptäckts. Den viktigaste 
riskfaktorn för magsäckscancer är infektion med magsäcksbakterien Helicobacter pylori. 
Ungefär hälften av alla människor i världen är infekterade med den här bakterien. I Sverige är 
det färre, ungefär 20 % av alla människor. Infektion med bakterien uppstår oftast i 
barndomen. Helicobacter pylori får man av andra människor, troligen när man delar mat och 
lever under ohygieniska levnadsvillkor. På grund av den förbättrade levnadsstandarden i 
Sverige har bakterien blivit mindre vanlig under de senaste decennierna. Helicobacter pylori 
kan även orsaka magsår. Besvär av magsår leder ofta till att bakterien blir upptäckt och 
behandlad. Behandlingen kallas för eradikering och genomförs med ett läkemedel som 
minskar syreproduktion i magen (protonpumpshämmare) i kombination med minst 2 
antibiotika. Det är dock få personer med Helicobacter pylori som får besvär av denna 
infektion, varför det inte är meningsfull att göra en utredning av alla människor och behandla. 
Behandlingen kan dock vara viktig för att minska risken för magsäckscancer hos vissa 
individer. På senare tid har studier visat att infektion med Helicobacter pylori kan minska 
risken för matstrupscancer, varför behandling av Helicobacter pylori skulle kunna öka risken 
för denna cancertyp. Matstrupscancer har blivit vanligare och är svår att bota. Studierna i den 
här avhandlingen försöker besvara frågor om behandling av Helicobacter pylori verkligen 
minskar risken för magsäckscancer, och om behandlingen ökar risken för matstrupscancer. 
Syftet med avhandlingen är att ge vetenskapligt underlag till och delvis besvara fråga om 
Helicobacter pylori ska behandlas eller inte.  
Studie I byggde på tidigare publicerade studier som undersökte om behandling av 
Helicobacter pylori minskar risken för magsäckscancer. Dessa studier valdes ut på ett 
systematiskt sätt för att säkerställa att alla relevanta studier hittades. Genom att sammansätta 
resultaten av flera studier ökas antalet deltagarna och antalet cancerfall, vilket gör resultaten 
mer pålitliga. De 8 inkluderade studierna, varav 7 från Japan och 1 från Finland, visade att 
risken för magsäckscancer minskades med ungefär 50 % efter behandling av Helicobacter 
pylori.  
Studie II byggde på ett nationell Svensk hälsodataregister (Läkemedelsregistret) vilket 
samlar in information för varje gång en person erhåller ett recept för ett läkemedel och hämtar 
ut det från apoteket. Den här studien beskriver hur behandling av Helicobacter pylori 
används i Sverige. Under perioden juli 2005 till december 2014 fick mer än 140 000 personer 
eradikering av Helicobacter pylori, vilket motsvarar 1,5 % av svenska befolkningen. De 
flesta människor (91 %) fick bara en behandling. I majoriteten (95 %) av behandlingarna 
användes standardantibiotika, som är rekommenderade för den här behandlingen. Samma 
standardantibiotika har också använts i andra eller tredje behandlingen.  
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Studie III och IV inkluderade personer som enligt Studie II hade fått 
eradikeringsbehandling. Ytterligare information om de här personerna inhämtades från andra 
nationella hälsodataregister som samlar in information om cancer (Cancerregistret), andra 
sjukdomar samt sjukhusvistelser (Patientregistret) och dödsfall (Dödsorsaksregistret). Risken 
för magsäckscancer var högre bland personer som fick eradikeringsbehandling jämfört med 
risken för magsäckscancer i resten av svenska befolkningen. Risken minskade dock med 
tiden och var omkring 70 % lägre från 5 år efter eradikeringsbehandling. Det fanns ganska få 
fall av matstrupscancer, vilket gjorde att resultaten inte var helt pålitliga. Därför studerade vi 
även risken för Barretts esofagus, ett förstadium till matstrupscancer som är betydligt 
vanligare än cancern. Både risken för matstrupscancer och Barretts esofagus minskade med 
tiden. Risken för Barretts esofagus verkade vara lägre än risken i svenska befolkningen från 5 
år efter eradikeringsbehandling.  
Slutsatser från den här avhandlingen är att behandling av Helicobacter pylori minskar risken 
för magsäckscancer. Det gäller både i Sverige och Asien, där människor växer upp och lever 
under olika levnadsförhållanden. Risken för matstrupscancer verkade inte vara förhöjd efter 
eradikeringsbehandling för Helicobacter pylori. Det betyder att Helicobacter pylori 
antagligen bör fortsätta behandlas hos de människor som behöver behandlingen. Det finns 
anledning att tro att behandling kan förbättras i Sverige, genom att använda andra antibiotika 
än de som användes när behandlingen inte fungerade första gången.        
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12 POPULAIR WETENSCHAPPELIJKE SAMENVATTING 
Helicobacter pylori: te behandelen of niet behandelen – dat is de vraag 
Maagkanker is een van de 5 meest voorkomende kankers ter wereld, en de meeste patiënten 
sterven gedurende de eerste 5 jaar na de diagnose. De belangrijkste risicofactor voor 
maagkanker is infectie met de bacterie Helicobacter pylori. Ongeveer de helft van de 
wereldbevolking draagt deze bacterie met zich mee. In Zweden is dat ongeveer 20% van de 
bevolking en in Nederland ongeveer 30%. De bacterie wordt vaak overgedragen op zeer 
jonge leeftijd. Overdracht van Helicobacter pylori gaat via menselijk contact, waarschijnlijk 
door het delen van eten en onhygiënische levensomstandigheden. Dankzij de verbetering in 
deze levensomstandigheden in Zweden komt de bacterie steeds minder voor, met een 
duidelijke daling tijdens de laatste decennia. Helicobacter pylori is ook verantwoordelijk 
voor het ontstaan van maagzweren. Het zijn de klachten van deze maagzweren die er vaak 
voor zorgen dat de bacterie gevonden en vervolgens behandeld wordt. Deze behandeling heet 
ook wel eradicatie en bestaat uit een maagzuurremmer in combinatie met ten minste 2 
verschillende soorten antibiotica. Het is echter maar een klein deel van de mensen met 
Helicobacter pylori die daadwerkelijk ziek wordt, en dus is het niet zinvol om iedereen op 
deze bacterie te testen en te behandelen. De behandeling kan echter wel van belang zijn om 
maagkanker te voorkomen. Maar sinds kort is het ook duidelijk geworden dat Helicobacter 
pylori het risico op slokdarmkanker juist lijkt te verminderen. Het idee is dus dat behandeling 
het risico op deze kankervorm kan verhogen maar dit werd nog niet eerder onderzocht. 
Slokdarmkanker komt de laatste jaren meer voor en is moeilijk te genezen, en heeft dus een 
nog slechtere prognose dan maagkanker. De studies in dit proefschrift proberen een antwoord 
te vinden op de vraag of behandeling van Helicobacter pylori het risico op maagkanker kan 
verkleinen, en of dit tegelijkertijd het risico op slokdarmkanker vergroot. Het doel was om 
door middel van wetenschappelijke studies dichterbij een antwoord op de vraag te komen of 
Helicobacter pylori behandeld moet worden of niet.  
Studie I is een overzichtsstudie gebaseerd op reeds gepubliceerde artikelen die onderzoeken 
of behandeling van Helicobacter pylori het risico op maagkanker verkleint. Deze artikelen 
zijn op een systematische manier geselecteerd om ervoor te zorgen dat alle relevante studies 
werden gevonden. Door de resultaten van meerdere studies samen te nemen wordt het aantal 
deelnemers en het aantal patiënten met kanker groter, waardoor de resultaten betrouwbaarder 
zijn. De 8 artikelen in deze studie, waarvan 7 afkomstig uit Japan en 1 uit Finland, lieten zien 
dat het risico op maagkanker ongeveer 50% lager was na het behandelen van Helicobacter 
pylori.  
Studie II is gebaseerd op een nationaal Zweeds zorgregister (het Zweedse 
geneesmiddelenregister) waarin informatie wordt ingezameld voor elke keer dat iemand een 
geneesmiddel op recept bij de apotheek ophaalt. De studie beschrijft hoe de behandeling van 
Helicobacter pylori wordt gegeven in Zweden. In de periode van juli 2005 tot en met 
december 2014 werden er meer dan 140 000 mensen behandeld met eradicatie, wat 
overeenkomt met 1,5% van de Zweedse bevolking. De meeste mensen (91%) werden slechts 
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één keer behandeld. In het grootste deel (95%) van de behandelingen werden de 
standaardantibiotica, die worden aanbevolen voor deze behandeling, gebruikt. Dezelfde 
antibiotica werden echter ook gebruikt voor tweede en derde behandelingen.  
Studie III en IV zijn gebaseerd op dezelfde groep mensen uit studie II die werden behandeld 
met eradicatie. Verdere informatie over deze personen kwam van andere nationale 
zorgregisters die informatie inzamelen over kanker (het Zweedse kankerregister), andere 
ziekten en opnames in het ziekenhuis (het Zweedse patiëntenregister) en sterfgevallen (het 
Zweedse doodsoorzakenregister). Het totale risico op maagkanker was verhoogd bij mensen 
die behandeld werden met eradicatie in vergelijking met de rest van de Zweedse bevolking. 
In de loop van de tijd werd het risico echter lager en vanaf 5 jaar na de eradicatie was het 
risico ongeveer 70% lager dan in de rest van de Zweedse bevolking. Het aantal gevallen van 
slokdarmkanker was laag, wat ervoor zorgde dat de resultaten niet geheel betrouwbaar waren. 
Daarom werd ook het risico op een Barrett slokdarm geëvalueerd, een aandoening waarbij de 
cellen in de slokdarm veranderen en wat zich kan ontwikkelen tot slokdarmkanker. Voor 
zowel slokdarmkanker als Barrett slokdarm werd het risico lager in de loop van de tijd. Het 
risico op Barrett slokdarm leek lager te zijn dan in de rest van de Zweedse bevolking vanaf 5 
jaar na de eradicatiebehandeling. 
De conclusies van dit proefschrift zijn dat behandeling van Helicobacter pylori het risico op 
maagkanker verkleint. Dit was het geval zowel in Zweden als in Azië, gebieden waar mensen 
in verschillende omstandigheden opgroeien en leven. Het risico op slokdarmkanker leek niet 
verhoogd te zijn na de behandeling van Helicobacter pylori. Dit betekent dat alle mensen met 
Helicobacter pylori die in aanmerking komen voor de behandeling ook behandeld moeten 
worden. Er is waarschijnlijk ruimte voor verbetering van de behandeling in Zweden, door 
andere antibiotica te gebruiken wanneer de behandeling de eerste keer niet slaagt.  
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